{"filing":{"accession_number":"0001213900-26-071711","cik":"0001885680","ticker":"RAJAF","company_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"ea0295908-6k_cordyceps.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885680/000121390026071711/ea0295908-6k_cordyceps.htm"},"events":[{"id":13668,"run_id":12136,"accession_number":"0001213900-26-071711","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This is a Cooperation and Development Agreement between Party A (Pet Sunshine Biological Research Co., Ltd., a Taiwan-registered entity) and Party B (Cordyceps Sunshine Biotech Holdings Co., Ltd., the Cayman Islands-registered filer). Party A grants Party B exclusive, irrevocable, worldwide rights to develop, commercialize, license, and manage the Antcin A platform (a next-generation non-steroidal anti-inflammatory drug platform) on a royalty-free basis, with 50/50 revenue sharing and preemptive/call options on future transactions. This constitutes a material strategic transaction involving transfer of exclusive commercialization and capital-markets development rights, even though legal ownership remains with Party A. The agreement explicitly contemplates future integration, M\u0026A, and restructuring, and grants Party B substantial control over a core asset platform.","company_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","ticker":"RAJAF","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":10876,"accession_number":"0001213900-26-071711","item_number":"EX-99.1","item_title":"ea029590801ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is a Cooperation and Development Agreement between Party A (Pet Sunshine Biological Research Co., Ltd., a Taiwan-registered entity) and Party B (Cordyceps Sunshine Biotech Holdings Co., Ltd., the Cayman Islands-registered filer). Party A grants Party B exclusive, irrevocable, worldwide rights to develop, commercialize, license, and manage the Antcin A platform (a next-generation non-steroidal anti-inflammatory drug platform) on a royalty-free basis, with 50/50 revenue sharing and preemptive/call options on future transactions. This constitutes a material strategic transaction involving transfer of exclusive commercialization and capital-markets development rights, even though legal ownership remains with Party A. The agreement explicitly contemplates future integration, M\u0026A, and restructuring, and grants Party B substantial control over a core asset platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:09:38.324328+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10876,"accession_number":"0001213900-26-071711","item_number":"EX-99.1","item_title":"ea029590801ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is a Cooperation and Development Agreement between Party A (Pet Sunshine Biological Research Co., Ltd., a Taiwan-registered entity) and Party B (Cordyceps Sunshine Biotech Holdings Co., Ltd., the Cayman Islands-registered filer). Party A grants Party B exclusive, irrevocable, worldwide rights to develop, commercialize, license, and manage the Antcin A platform (a next-generation non-steroidal anti-inflammatory drug platform) on a royalty-free basis, with 50/50 revenue sharing and preemptive/call options on future transactions. This constitutes a material strategic transaction involving transfer of exclusive commercialization and capital-markets development rights, even though legal ownership remains with Party A. The agreement explicitly contemplates future integration, M\u0026A, and restructuring, and grants Party B substantial control over a core asset platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:09:38.324328+00:00","company_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","ticker":"RAJAF","filing_date":"2026-06-25"}]}